According to the results of this meta-analysis, the combination therapy significantly prolonged PFS (Fig. 2A), but did not prolong OS (Fig. 2B) compared to monotherapy for advanced EGFR-mutant NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.